comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 05:30:45 - browse：25748

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Philips to halt sales of sleep apnea machines in U.S.

hotspot

WSS

Intermittent fasting comes with a heart risk? Not so fast

5 to watch: Tech startups trying to solve health care's staffing crisis

Syphilis numbers in the United States reach record heights

The Affordable Care Act has saved billions in health care costs

5 to watch: Tech startups trying to solve health care's staffing crisis

Vertex non

hotspot

comprehensive

hotspot

Cancer drug shortages should be causing more outrage

Health Care Service Corp to buy Cigna Medicare Advantage plans

As demand for Covid shots wanes, Moderna seeks its next success

Vertex non

After affirmative action ruling, medical educators look to 'holistic review'

Asbestos, a deadly carcinogen, banned by EPA

Alkermes shareholders re

Baby aspirin cuts fat buildup in liver disease patients, in small study

United colonoscopy coverage change 'may cost lives,' doctors say

Health AI adoption puts security, privacy startups on investors' radar

entertainment

U.K. researchers warn about biases in medical devices, algorithms

Biogen walks away from Aduhelm, years after polarizing approval

Boston competes with Raleigh

10 reasons why health care startups fail

Zyn nicotine pouches become unlikely player in latest culture war

Merck CEO won’t testify in Senate, citing no expertise in drug prices

hotspot

hotspot

knowledge

leisure time